Bronchiolitis obliterans organizing pneumonia in the patient with non-small cell lung cancer treated with docetaxel/cisplatin chemotherapy: A case report

Tuberculosis and Respiratory Diseases

Volumn 69, Issue 4, 2010, Pages 293-297

  Kim, Ae Ran ^a   Kim, Tae Young ^b   Lee, Young Min ^b   Lee, Seung Heon ^b   Jung, Soo Jin ^b   Lee, Hyun Kyung ^b  

^a Inje University College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

Cryptogenic organizing pneumonia; Docetaxel; Drug therapy; Lung neoplasms

Indexed keywords

ANTIBIOTIC AGENT; CISPLATIN; CORTICOSTEROID; DOCETAXEL;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SIZE; CANCER STAGING; CASE REPORT; CAUSE OF DEATH; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DRUG MEGADOSE; DYSPNEA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOXEMIA; LUNG BIOPSY; LUNG INFILTRATE; LUNG LAVAGE; LUNG LESION; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPHADENOPATHY; LYMPHOCYTE COUNT; MALE; MEDIASTINUM LYMPH NODE; MULTIPLE CYCLE TREATMENT; POOR GENERAL CONDITION; RESPIRATORY FAILURE;

EID: 78649338003     PISSN: 17383536     EISSN: None     Source Type: Journal    
DOI: 10.4046/trd.2010.69.4.293     Document Type: Article

References (15)

1. Pavlakis N, Bell DR, Millward MJ, Levi JA. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997;80:286-91.
2. Merad M, Le Cesne A, Baldeyrou P, Mesurolle B, Le Chevalier T. Docetaxel and interstitial pulmonary injury. Ann Oncol 1997;8:191-4.
3. Takeda K, Negoro S, Tamura T, Nishiwaki Y, Kudoh S, Yokota S, et al. Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104). Ann Oncol 2009;20:835-41.
4. Taxane-induced pulmonary toxicity. UpToDate version 14.3. [Internet]. Waltham: UpToDate Inc.; c2010 [cited 2010 Oct 8]. Available from: http://www.uptodate.com.
5. Ravdin PM, Burris HA 3rd, Cook G, Eisenberg P, Kane M, Bierman WA, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995;13:2879-85.
6. Kouroussis C, Mavroudis D, Kakolyris S, Voloudaki A, Kalbakis K, Souglakos J, et al. High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. Lung cancer 2004;44:363-8.
7. Chen YM, Shih JF, Perng RP, Tsai CM, Whang-Peng J. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest 2006;129:1031-8.
8. Onishi H, Kuriyama K, Yamaguchi M, Komiyama T, Tanaka S, Araki T, et al. Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis. Lung cancer 2003;40:79-84.
9. Dunsford ML, Mead GM, Bateman AC, Cook T, Tung K. Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol 1999;10:943-7.
10. Read WL, Mortimer JE, Picus J. Severe interstitial pneumonitis associated with docetaxel administration. Cancer 2002;94:847-53.
11. Veltkamp SA, Meerum Terwogt JM, van den Heuvel MM, van Boven HH, Schellens JH, Rodenhuis S. Severe pulmonary toxidty in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel. Invest New Drugs 2007;25:279-81.
12. Epler GR, Colby TV, McLoud TC, Carrington CB, Gaensler EA. Bronchiolitis obliterans organizing pneumonia. N Engl J Med 1985;312:152-8.
13. Santrach PJ, Askin FB, Wells RJ, Azizkhan RG, Merten DF. Nodular form of bleomycin-related pulmonary injury in patients with osteogenic sarcoma. Cancer 1989;64:806-11.
14. Jacobs C, Slade M, Lavery B. Doxorubicin and BOOP. A possible near fatal association. Clin Oncol (R Coll Radiol) 2002;14:262.
15. Lazor R, Vandevenne A, Pelletier A, Leclerc P, Court-Fortune I, Cordier JF. Cryptogenic organizing pneumonia. Characteristics of relapses in a series of 48 patients. The Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). Am J Respir Crit Care Med 2000;162:571-7.